Assessing brain hemodynamics using Arterial Spin Labeling.

Completed

Conditions: Cerebrovascular disease
stroke
10003216

Registration Number: NL-OMON37548

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 180

Inclusion Criteria

Inclusion criteria for the healthy volunteers:
- 18 years or older
- male or female
- informed consent after extensive explanation about the device and the research protocol
- healthy;Inclusion criteria for patients:
- 18 years or older
- male or female
- (A)symptomatic extracranial vascular disease (stenosis of 70-100%)
or
Symptomatic middle cerebral artery occlusion
- Informed consent after extensive explanation about the device and the research protocol
- healthy

Exclusion Criteria

Exclusion criteria for the healthy volunteers:
- Contraindications for MRI (claustrophobia, or standard MRI contraindications such as pacemakers or specific metal objects in or around the body)
- Previous history of ischemic symptoms
- Minors or (legally) incompetent adults;Exclusion criteria for patients:
- Contraindications for MRI (claustrophobia, or standard MRI contraindications such as pacemakers or specific metal objects in or around the body)
- Unwilling or unable to co-operate with breathing manoeuvres
- Known cardiac or pulmonary disease
- altered consciousness
- Non compliance with prescribed anti-seizure medication
- Minors or (legally) incompetent adults

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoint in part 1 is to test the feasibility and safety of the<br /><br>CO2-challenge in healthy volunteers. During this part we will also optimize the<br /><br>sequences and the scan protocol.<br /><br><br /><br>In part 2 of this research the CVR and the OEF in the different patient<br /><br>populations will be compared with the CVR and OEF in the control group.</p><br>

Secondary Outcome Measures